REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 10th, 2023 • Virax Biolabs Group LTD • In vitro & in vivo diagnostic substances
This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 8, 2023, between Virax Biolabs Group Limited, a Cayman Islands exempted company (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
ORDINARY SHARE PURCHASE WARRANT VIRAX BIOLABS GROUP LIMITEDVirax Biolabs Group LTD • October 12th, 2023 • In vitro & in vivo diagnostic substances • New York
THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _____, 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Virax Biolabs Group Limited, a Cayman Islands exempted company (the “Company”), up to ______ Ordinary Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 8th, 2022 • Virax Biolabs Group LTD • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 3, 2022, between Virax Biolabs Group Limited, a Cayman Islands exempted company (the “Company”), and the purchaser identified on the signature page hereto (including its successors and assigns, the “Purchaser”).
1,350,000 ORDINARY SHARES VIRAX BIOLABS GROUP LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • July 26th, 2022 • Virax Biolabs Group LTD • In vitro & in vivo diagnostic substances • New York
The undersigned, Virax Biolabs Group Limited, a company incorporated under the laws of the Cayman Islands (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Virax Biolabs Group Limited, the “Company”), hereby confirms its agreement (this “Agreement ”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Boustead Securities, LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
AT THE MARKET OFFERING AGREEMENTMarket Offering Agreement • January 22nd, 2024 • Virax Biolabs Group LTD • In vitro & in vivo diagnostic substances • New York
INDEPENDENT DIRECTOR AGREEMENTIndependent Director Agreement • November 18th, 2022 • Virax Biolabs Group LTD • In vitro & in vivo diagnostic substances • New York
This DIRECTOR AGREEMENT (the “Agreement”) is made and entered into as of this 17th day of November, 2022, (the “Effective Date”) by and between Virax Biolabs Group Limited, a Cayman Islands corporation (the “Company”), and Nelson Haight, (the “Independent Director”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 23rd, 2024 • Virax Biolabs Group LTD • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 21, 2024, between Virax Biolabs Group Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Dated the 1st day of September 2023 VIRAX BIOLABS GROUP LIMITED and DR NIGEL MCCRACKEN EMPLOYMENT AGREEMENT FOR EXECUTIVE OFFICEREmployment Agreement • September 1st, 2023 • Virax Biolabs Group LTD • In vitro & in vivo diagnostic substances
VIRAX BIOLABS GROUP LIMITED, a company incorporated in Cayman Islands with limited liability with registered address at 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands (the “Company”); and
ORDINARY SHARE PURCHASE WARRANT VIRAX BIOLABS GROUP LIMITEDVirax Biolabs Group LTD • August 23rd, 2024 • In vitro & in vivo diagnostic substances
THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 21, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Virax Biolabs Group Limited, a Cayman Islands exempted company (the “Company”), up to ______ Ordinary Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Engagement Agreement by and between the Company and H.C. Wainwright & Co., LLC, dated as of June 6, 2024.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 10th, 2023 • Virax Biolabs Group LTD • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 8, 2023, between Virax Biolabs Group Limited, a Cayman Islands exempted company (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SERIES B PREFERRED INVESTMENT OPTION VIRAX BIOLABS GROUP LIMITEDVirax Biolabs Group LTD • March 10th, 2023 • In vitro & in vivo diagnostic substances
THIS SERIES B PREFERRED INVESTMENT OPTION (the “Preferred Investment Option”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _____, 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Virax Biolabs Group Limited, a Cayman Islands exempted company (the “Company”), up to ______ Ordinary Shares (as subject to adjustment hereunder, the “Preferred Investment Option Shares”). The purchase price of one Ordinary Share under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2(b).
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • March 18th, 2022 • Virax Biolabs Group LTD • In vitro & in vivo diagnostic substances
NOW THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, and intending to be legally bound hereby, the Parties agree as follows:
VIRTUAL OFFICE AGREEMENTVirtual Office Agreement • March 18th, 2022 • Virax Biolabs Group LTD • In vitro & in vivo diagnostic substances • England and Wales
